NCT04918602

Brief Summary

The primary goal of this research project is to develop different prediction models in fibromyalgia disease through the application of machine learning techniques and to assess the explainability of the results. As specific objectives the research project intends: to predicting Fibromyalgia severity of patients based on clinical variables; to assess the relevance of social-psycho-demographic variables on the fibromyalgia severity of the patients; to predict the pain suffered by the patients as well as the impact of the fibromyalgia on patient's life; to categorize fibromyalgia group of patients depending on their levels of Fibromyalgia severity.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2021

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

June 2, 2021

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 9, 2021

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2021

Completed
Last Updated

June 9, 2021

Status Verified

June 1, 2021

Enrollment Period

5 months

First QC Date

June 2, 2021

Last Update Submit

June 2, 2021

Conditions

Outcome Measures

Primary Outcomes (3)

  • Pain intensity

    It will be measured with a visual analog scale (VAS) of 100 millimeters in length. The subject has to indicate the level ofpain he feels, being 0 the absence of pain and 100 the maximum imaginable.

    Baseline.

  • Disease severity.

    It will be measured using the Polysymptomatic Distress Scale (PDS) (or Fibromyalgia Severity Scale), composed of the sum of the following two scales: 1. Widespread Pain Index (WPI): Questionnaire in which a total of 19 body areas are represented. The subject has to mark the regions where the pain appears. It represents a measure of the extent of pain, with a maximum score of 19 points. 2. Symptom Severity Scale (SSS): Questionnaire that measures the severity of the symptoms associated with fibromyalgia, such as fatigue, non-restorative sleep, cognitive problems, headaches, abdominal pain or cramps and depression. It represents a measure of somatic and non-somatic symptoms of fibromyalgia, with a maximum score of 12 points.

    Baseline.

  • Referred pain area after suprathreshold pressure stimulation.

    A pressure algometer (Force Ten™, Wagner Instruments, USA) will be used. It will be performed on the infraspinatus muscle (point equidistant between the midpoint of the spine of the scapula, the inferior angle of the scapula and the midpoint of the medial border of the scapula) at a constant suprathreshold pressure (20% above the pressure pain threshold) for 60 seconds. After the stimulation, the subject should draw the induced pain area on a digital bodychart using the Navigate Pain application (Navigate Pain, Aalborg University, Denmark).

    Baseline.

Secondary Outcomes (4)

  • Fibromyalgia Impact Quality-of-Life.

    Baseline.

  • Anxiety.

    Baseline.

  • Pain catastrophizing.

    Baseline.

  • Depression.

    Baseline.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Members enrolled in a local fibromyalgia association.

You may qualify if:

  • Age between 18 and 65 years.
  • Fullfilled the 2010 American Collegue of Rheumathology criteria for fibromyalgia.
  • Understanding of spoken and written Spanish.

You may not qualify if:

  • Diagnosed psychiatric pathology.
  • Rheumatic pathology not medically controlled.
  • Neurological pathologies that make evaluations difficult.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital General Nuestra Señora del Prado

Talavera de la Reina, Toledo, 45600, Spain

Location

MeSH Terms

Conditions

Fibromyalgia

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeuromuscular DiseasesNervous System Diseases

Central Study Contacts

Rubén Arroyo Fernández, MSc

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 2, 2021

First Posted

June 9, 2021

Study Start

June 1, 2021

Primary Completion

November 1, 2021

Study Completion

November 1, 2021

Last Updated

June 9, 2021

Record last verified: 2021-06

Locations